Your browser is old and is not supported. Upgrade for better security.

Invest in Sen-Jam Pharmaceutical

Own a Revolutionary Stake for Health Equality; Affordable, Accessible for All!

In the news

Sen-Jam Pharmaceutical Planning to Trial Oral COVID Therapy
October 12, 2021
HUNTINGTON, N.Y., Oct. 12, 2021 /PRNewswire/ -- Excessive inflammation is a hallmark of severe COVID-19. When confronted with the virus, the immune system can enter a hyper-inflammatory state as a "cytokine storm"; uncontrolled inflammation leading to acute respiratory distress syndrome (ARDS) and death.
What People Say